チグリタザール/メトホルミン徐放錠の食事影響および多回投与研究
Chiglitazar/Metformin持続性放出固定用量配合錠剤の食事効果および多回投与薬物動態を評価する第I相臨床試験
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study.
The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants.
The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、101300
- Beijing Ditan Hospital, Capital Medical University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy male or female participants;
- Age from 18 to 45 years, inclusive;
- Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
- From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures;
- Voluntarily agrees to participate in the study and signs the informed consent form.
Exclusion Criteria:
- Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
- Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products;
- Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
- Surgery within 3 months prior to screening or planned surgery during the study period;
- Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
- History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
- Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
- Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
- History of drug or substance abuse, or a positive alcohol or urine drug screening test;
- Intolerance to venipuncture, or a history of fainting in response to needles or blood;
- Fasting blood glucose > 6.1 mmol/L or < 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
- Participation in any interventional clinical trial within 3 months prior to screening;
- Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
- Pregnant or lactating women;
- Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
- Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
- Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
- Glomerular Filtration Rate (GFR) < 90 mL/min/1.73 m²;
- Systolic blood pressure < 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure < 50 mmHg or ≥ 90 mmHg at screening;
- Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
- Plans to or is required to engage in strenuous physical activity or exercise during the study period;
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:FE試験のシーケンス1
|
a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal |
|
実験的:FE試験のシーケンス2
|
a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal |
|
実験的:多回投与群
|
a single dose on Day 1, once-daily consecutive doses from Day 4 to Day 10 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
FE試験:最高血漿濃度(Cmax)
時間枠:投与前および投与後72時間までの複数の時点で
|
投与前および投与後72時間までの複数の時点で
|
|
FE研究:血漿中濃度-時間曲線下面積(AUC)
時間枠:投与前および投与後72時間までの複数の時点で
|
投与前および投与後72時間までの複数の時点で
|
|
FE試験:最高血中濃度到達時間(Tmax)
時間枠:投与前および投与後72時間までの複数の時点で
|
投与前および投与後72時間までの複数の時点で
|
|
FE試験:消失半減期(t1/2)
時間枠:投与前および投与後72時間までの複数の時間点
|
投与前および投与後72時間までの複数の時間点
|
|
FE研究:見かけの総クリアランス(CL/F)
時間枠:投与前および投与後72時間までの複数の時点
|
投与前および投与後72時間までの複数の時点
|
|
FE試験:終末相における見かけの分布容積(Vz/F)
時間枠:投与前および投与後最大72時間までの複数の時点で
|
投与前および投与後最大72時間までの複数の時点で
|
|
多回投与PK試験:最高血漿中濃度(Cmax)
時間枠:最終投与前から最終投与後72時間まで(7日間連続投与)
|
最終投与前から最終投与後72時間まで(7日間連続投与)
|
|
複数回投与薬物動態研究:血漿中濃度-時間曲線下面積(AUC)
時間枠:最終投与前から最終投与後72時間まで(連続7日間の投与)
|
最終投与前から最終投与後72時間まで(連続7日間の投与)
|
|
複数回投与PK試験:最高血漿中濃度到達時間(Tmax)
時間枠:最終投与前から最終投与後72時間まで(連続7日間の投与)
|
最終投与前から最終投与後72時間まで(連続7日間の投与)
|
|
多回投与PK試験:定常状態における最高血中濃度(Cmax,ss)
時間枠:最終投与前から最終投与後72時間まで(7日間連続投与)
|
最終投与前から最終投与後72時間まで(7日間連続投与)
|
|
多回投与PK試験:定常状態における最高血中濃度到達時間(Tmax,ss)
時間枠:最終投与前から最終投与後72時間まで(7日間連続投与)
|
最終投与前から最終投与後72時間まで(7日間連続投与)
|
|
多回投与PK試験:定常状態における血漿中濃度-時間曲線下面積(AUCss)
時間枠:最終投与後72時間までの投与前(7日間連続投与)
|
最終投与後72時間までの投与前(7日間連続投与)
|
|
多回投与PK試験:トラフ濃度(Ctrough)
時間枠:最終投与後72時間までの投与前(7日間連続投与)
|
最終投与後72時間までの投与前(7日間連続投与)
|
|
多回投与PK試験:蓄積比(Rac)
時間枠:最終投与前から最終投与後72時間まで(連続7日間の投与)
|
最終投与前から最終投与後72時間まで(連続7日間の投与)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
有害事象(AEs)の発生率
時間枠:Day 16まで
|
Day 16まで
|
|
|
Change from baseline in hematology parameters: white blood cell count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count , hemoglobin, hematocrit, platelet count
時間枠:up to Day 13
|
Change from baseline in hematology parameters: white blood cell count (WBC), neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count (RBC), hemoglobin (Hb), hematocrit (HCT), platelet count (PLT) |
up to Day 13
|
|
Changes from baseline in serum chemistry parameters
時間枠:up to Day 13
|
Changes from baseline in serum chemistry parameters: fasting blood glucose (FBG), total protein, albumin, total bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN) or urea, uric acid, creatinine, potassium (K⁺), sodium (Na⁺), chloride (Cl-), creatine kinase (CK) |
up to Day 13
|
|
Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells
時間枠:up to Day 13
|
Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells (RBCs) |
up to Day 13
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。